骨髓增生异常综合征门诊患者红细胞输注可行性探索性随机试验
该研究在英国、澳大利亚和新西兰12个中心随机38例MDS门诊患者,比较限制性(80 g/l)与宽松性(105 g/l)红细胞输注阈值的可行性及生活质量。主要结局为输注阈值依从性,限制性组86%(95%CI 75-94%),宽松性组99%(95-100%)。探索性分析显示宽松性组五个主要生活质量域改善,支持开展确定性试验。
要点
- 门诊MDS患者随机接受限制性或宽松性红细胞输注阈值可行
- 限制性组依从性86%,宽松性组99%
- 宽松性组生活质量五个主要域有改善趋势
核心结论
- 在MDS门诊患者中开展不同红细胞输注阈值的随机试验可行,且需要确定性试验评估对患者中心结局的影响。
研究设计与样本
- 多中心探索性随机试验,纳入38例MDS患者(限制性组20例,宽松性组18例),来自英国、澳大利亚和新西兰12个中心。
主要发现
- 限制性组依从性86%(95%CI 75-94%),宽松性组99%(95-100%)。
- 限制性组平均输注前血红蛋白80 g/l(SD6),宽松性组97 g/l(SD7)。
- 研究期间限制性组输注红细胞82单位,宽松性组192单位。
- 探索性分析显示宽松性组五个主要生活质量域较限制性组改善。
关键数值与推荐
- 限制性阈值80 g/l,维持血红蛋白85-100 g/l;宽松性阈值105 g/l,维持血红蛋白110-125 g/l。
临床怎么用
- 结果支持在MDS门诊患者中进一步开展确定性试验,比较不同输血阈值对生活质量等患者中心结局的影响。
局限性
- 探索性研究样本量小(38例),生活质量分析为探索性,结论需确定性试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimal red cell transfusion support in myelodysplastic syndromes (MDS) has not been tested and established. The aim of this study was to demonstrate feasibility of recruitment and follow-up in an outpatient setting with an exploratory assessment of quality of life (QoL) outcomes (EORTC QLQ-C30 and EQ-5D-5L). We randomised MDS patients to standardised transfusion algorithms comparing current restrictive transfusion thresholds (80 g/l, to maintain haemoglobin 85-100 g/l) with liberal thresholds (105 g/l, maintaining 110-125 g/l). The primary outcomes were measures of compliance to transfusion thresholds. Altogether 38 patients were randomised (n = 20 restrictive; n = 18 liberal) from 12 participating sites in UK, Australia and New Zealand. The compliance proportion for the intention-to-treat population was 86% (95% confidence interval 75-94%) and 99% (95-100%) for restrictive and liberal arms respectively. Mean pre-transfusion haemoglobin concentrations for restrictive and liberal arms were 80 g/l (SD6) and 97 g/l (SD7). The total number of red cell units transfused on study was 82 in the restrictive and 192 in the liberal arm. In an exploratory analysis, the five main QoL domains were improved for participants in the liberal compared to restrictive arm. Our findings support the feasibility and need for a definitive trial to evaluate the effect of different red cell transfusion thresholds on patient-centred outcomes.
引用
- Stanworth SJ, Killick S, McQuilten ZK, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020. PMID: 31960409. doi:10.1111/bjh.16347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。